Recent Updates
Recently added Catalysts
RVMD Positive Sentiment

Revolution Medicines to Participate in March 2025 Investor Conferences

Monday, February 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revolution Medicines, Inc. will participate in several investor conferences in March 2025, showcasing its commitment to engaging with the investment community. CEO Mark A. Goldsmith will be featured in fireside chats at three notable conferences. These events will allow the company to present its progress in developing targeted therapies for RAS-addicted cancers, reflecting its active role in oncology. Archived webcasts will be available on the company's website following each event.
Price reaction · baseline $41.34 (2025-02-21 close) · 1 other RVMD headline(s) in the window, move may be shared
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple high-profile investor conferences indicates strong engagement with the investment community.
  • Revolution Medicines is focusing on targeted therapies for RAS-addicted cancers, showing a commitment to advancing oncology treatments.
  • The events provide a platform for the CEO to communicate the company's progress and vision directly to investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
6.7%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
daraxonrasib
Phase 3 · NSCLC (Non-small Cell Lung Cancer)

Full Press Release Details

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences.
Details of the company’s participation are as follows:
TD Cowen 45th Annual Healthcare Conference Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
Barclays 27th Annual Global Healthcare Conference Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
2025 Leerink Partners Global Healthcare Conference Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines Media & Investor Contact:

Frequently Asked Questions

What company is participating in upcoming investor conferences?

Revolution Medicines, Inc. will attend several investor conferences.

Who is the CEO of Revolution Medicines?

Mark A. Goldsmith, M.D., Ph.D. is the CEO and chairman of Revolution Medicines.

When is Revolution Medicines' first conference appearance?

The first appearance is on March 3 at the TD Cowen Healthcare Conference.

How can I access live webcasts of the events?

Live webcasts can be accessed on Revolution Medicines' investor website.

Where can I find archived webcasts?

Archived webcasts will be available for at least 14 days on their website.

ShareAdd on Google
Tags: RVMD Viatris Investor Conferences Healthcare Revolution Medicines oncology RAS-addicted cancers investor conferences
Last updated: Feb 24, 2025

Biotech snapshot

Cash runway
$3938M liquidity · $129M/mo burn
~30 mo
Minimal dilution risk
Lead asset
daraxonrasibPhase 3
NSCLC (Non-small Cell Lung Cancer) →

Catalyst track record

+124%
best trade around RVMD's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for RVMD.

See every catalyst's timing & PoA →